Cargando…
The Small Molecule Ephrin Receptor Inhibitor, GLPG1790, Reduces Renewal Capabilities of Cancer Stem Cells, Showing Anti-Tumour Efficacy on Preclinical Glioblastoma Models
Therapies against glioblastoma (GBM) show a high percentage of failure associated with the survival of glioma stem cells (GSCs) that repopulate treated tumours. Forced differentiation of GSCs is a promising new approach in cancer treatment. Erythropoietin-producing hepatocellular (Eph) receptors dri...
Autores principales: | Gravina, Giovanni Luca, Mancini, Andrea, Colapietro, Alessandro, Delle Monache, Simona, Sferra, Roberta, Vitale, Flora, Cristiano, Loredana, Martellucci, Stefano, Marampon, Francesco, Mattei, Vincenzo, Beirinckx, Filip, Pujuguet, Philippe, Saniere, Laurent, Lorenzon, Giocondo, van der Aar, Ellen, Festuccia, Claudio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468443/ https://www.ncbi.nlm.nih.gov/pubmed/30871240 http://dx.doi.org/10.3390/cancers11030359 |
Ejemplares similares
-
Antitumorigenic Effects of Inhibiting Ephrin Receptor Kinase Signaling by GLPG1790 against Colorectal Cancer Cell Lines In Vitro and In Vivo
por: Colapietro, Alessandro, et al.
Publicado: (2020) -
Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cells
por: Megiorni, Francesca, et al.
Publicado: (2017) -
The Brain Penetrating and Dual TORC1/TORC2 Inhibitor, RES529, Elicits Anti-Glioma Activity and Enhances the Therapeutic Effects of Anti-Angiogenetic Compounds in Preclinical Murine Models
por: Gravina, Giovanni Luca, et al.
Publicado: (2019) -
Multiple Antitumor Molecular Mechanisms Are Activated by a Fully Synthetic and Stabilized Pharmaceutical Product Delivering the Active Compound Sulforaphane (SFX-01) in Preclinical Model of Human Glioblastoma
por: Colapietro, Alessandro, et al.
Publicado: (2021) -
The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma
por: Gravina, Giovanni Luca, et al.
Publicado: (2017)